Cardiovascular Blockbusters Are Built, Not Born, Novartis COO Says Of Tekturna
This article was originally published in The Pink Sheet Daily
Global economy had little impact on conservative Novartis in 2008, CFO says.
You may also be interested in...
Review of application for ages 11 and up proceeds, but the agency wants to see more data on infants, pushing a second filing for the meningitis vaccine to 2011 in the U.S.
Commercialization of the fixed-dose combo buys lifecycle management for Forest and should support future drug development for partner Adamas, the originator of the technology behind the combination.